Immutep (IMMP) Competitors $1.91 -0.02 (-1.04%) Closing price 04:00 PM EasternExtended Trading$1.93 +0.02 (+1.05%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMMP vs. SPRY, AUPH, SNDX, SYRE, ELVN, COLL, BCYC, NTLA, RCKT, and ZYMEShould you be buying Immutep stock or one of its competitors? The main competitors of Immutep include ARS Pharmaceuticals (SPRY), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Rocket Pharmaceuticals (RCKT), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Immutep vs. ARS Pharmaceuticals Aurinia Pharmaceuticals Syndax Pharmaceuticals Spyre Therapeutics Enliven Therapeutics Collegium Pharmaceutical Bicycle Therapeutics Intellia Therapeutics Rocket Pharmaceuticals Zymeworks ARS Pharmaceuticals (NASDAQ:SPRY) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership. Which has more volatility & risk, SPRY or IMMP? ARS Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Does the media prefer SPRY or IMMP? In the previous week, ARS Pharmaceuticals had 8 more articles in the media than Immutep. MarketBeat recorded 9 mentions for ARS Pharmaceuticals and 1 mentions for Immutep. ARS Pharmaceuticals' average media sentiment score of 0.41 beat Immutep's score of 0.33 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immutep 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in SPRY or IMMP? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 2.3% of Immutep shares are held by institutional investors. 40.1% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend SPRY or IMMP? ARS Pharmaceuticals currently has a consensus target price of $26.00, indicating a potential upside of 99.69%. Immutep has a consensus target price of $8.50, indicating a potential upside of 341.56%. Given Immutep's higher probable upside, analysts plainly believe Immutep is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer SPRY or IMMP? Immutep received 291 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 84.00% of users gave ARS Pharmaceuticals an outperform vote while only 72.56% of users gave Immutep an outperform vote. CompanyUnderperformOutperformARS PharmaceuticalsOutperform Votes2184.00% Underperform Votes416.00%ImmutepOutperform Votes31272.56% Underperform Votes11827.44% Which has stronger earnings & valuation, SPRY or IMMP? Immutep has higher revenue and earnings than ARS Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$30K42,176.12-$54.37M-$0.51-25.53Immutep$5.14M54.51-$28.01MN/AN/A Is SPRY or IMMP more profitable? Immutep's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS PharmaceuticalsN/A -22.56% -21.82% Immutep N/A N/A N/A SummaryARS Pharmaceuticals beats Immutep on 9 of the 16 factors compared between the two stocks. Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricImmutepPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.47M$6.55B$5.38B$9.11BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.7087.8117.51Price / Sales54.51334.591,285.9980.25Price / CashN/A22.6336.6032.90Price / Book1.835.064.944.66Net Income-$28.01M$154.90M$117.96M$224.69M7 Day Performance-0.26%2.31%2.29%3.11%1 Month Performance-5.17%1.25%3.26%5.17%1 Year Performance-14.82%4.88%27.03%22.24% Immutep Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPImmutep1.2661 of 5 stars$1.91-1.0%$8.50+345.0%-14.6%$278.02M$5.14M0.002,021News CoverageSPRYARS Pharmaceuticals2.8814 of 5 stars$11.42+1.6%$24.50+114.5%+107.8%$1.11B$2.57M-22.3990AUPHAurinia Pharmaceuticals2.9741 of 5 stars$7.75-4.0%$10.00+29.0%+0.1%$1.11B$220.36M-51.66300Positive NewsSNDXSyndax Pharmaceuticals3.7635 of 5 stars$12.74-2.8%$36.20+184.1%-36.8%$1.09B$16M-3.51110SYRESpyre Therapeutics2.2314 of 5 stars$21.14-5.9%$51.50+143.6%-14.5%$1.09B$890,000.00-2.83100ELVNEnliven Therapeutics2.0463 of 5 stars$22.13+1.8%$38.25+72.8%+50.0%$1.08BN/A-11.6550COLLCollegium Pharmaceutical4.253 of 5 stars$33.43+1.6%$43.80+31.0%+1.1%$1.08B$599.25M14.41210BCYCBicycle Therapeutics3.0507 of 5 stars$14.89+11.9%$34.50+131.7%-24.8%$1.03B$36.90M-4.53240Gap UpNTLAIntellia Therapeutics4.6639 of 5 stars$9.98-2.2%$51.56+416.7%-62.8%$1.02B$43.09M-1.83600RCKTRocket Pharmaceuticals4.5143 of 5 stars$10.82-2.9%$47.27+336.9%-61.2%$986.32MN/A-3.93240ZYMEZymeworks3.8872 of 5 stars$13.85+4.8%$19.17+38.4%+40.5%$953.96M$62.20M-9.23290Positive News Related Companies and Tools Related Companies ARS Pharmaceuticals Alternatives Aurinia Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Spyre Therapeutics Alternatives Enliven Therapeutics Alternatives Collegium Pharmaceutical Alternatives Bicycle Therapeutics Alternatives Intellia Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Zymeworks Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMMP) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
